Lymphoma, non-Hodgkin, familial
Therapeutic area
Hematology
Rare disease
No
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Lymphoma, non-Hodgkin, familial
- Therapeutic area
- Hematology
- lymphoma, non-Hodgkin, familial
- lymphoma, follicular, somatic
- lymphoma, non-Hodgkin
- lymphoma, non-Hodgkin, familial
- lymphoma, non-Hodgkin, somatic
- Severity
- Severe
- Hematology
- Oncology
- MONDO ID
- MONDO:0011508
- Parent condition
- MONDO:0018908
Related records
Broader conditions (14)
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Lymphoid hemopathy
- Lymphoid neoplasm
- Lymphoma
- Neoplasm
- Neoplastic disease or syndrome
- Non-Hodgkin lymphoma
Trials (2,280)
- 'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL
- (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
- (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).
- 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
- 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
- 124I-FIAU Imaging in EBV and KSHV Associated Cancers
- 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients
- 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
- 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
- 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
- 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
- 3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
- 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
- 64Cu-LLP2A for Imaging Hematologic Malignancies
- 9-ING-41 in Patients With Advanced Cancers
Drugs in development (1)
- Ortataxel Phase 2
Other linked drugs (5)
- Carmustine
- Idelalisib
- Melphalan
- Rituximab
- Romidepsin